Company: IPSC
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001104659-25-037419
Chunk: 26

Company: Century Therapeutics, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 26
---
 | ​ |                         59,000 | ​ | ​ |                 81,092 | ​ | ​ |   140,092 | ​ | ​ |
| ​ | ​ | Alessandro Riva, M.D.    | ​ | ​ |                         47,500 | ​ | ​ |                 81,092 | ​ | ​ |   128,592 | ​ | ​ |
| ​ | ​ | Carlo Rizzuto, Ph.D.     | ​ | ​ |                         54,000 | ​ | ​ |                 81,092 | ​ | ​ |   135,092 | ​ | ​ |
| ​ | ​ | Timothy P. Walbert       | ​ | ​ |                         45,000 | ​ | ​ |                 81,092 | ​ | ​ |   126,092 | ​ | ​ |

(1) Amounts shown in this column do not reflect dollar amounts actually received by our directors. Instead, these amounts reflect the aggregate grant date fair value of each stock option granted in 2024 determined in accordance with the provisions of Financial Accounting Standards Board Accounting Standards, Codification Topic 718, Compensation — Stock Compensation, or FASB ASC Topic 718. The assumptions made in the calculation of these amounts are included in Note 2 of the Notes to Consolidated Financial Statements included in our 2024 Annual Report. (2) As of December 31, 2024, Dr. Rizzuto held options to purchase 147,616 shares of our common stock; Ms. Butitta and Mr. Jimenez each held options to purchase 127,744 shares of our common stock; Dr. Riva and Dr. Blackwell each held options to purchase 227,227 shares of our common stock; and Mr. Walbert and Ms. Quimi each held options to purchase 127,744 shares of our common stock. As of December 31, 2024, Ms. Butitta held unvested stock awards totaling 24,734 shares of restricted stock.

Notice of Annual Meeting of Stockholders and 2025 Proxy Statement | 17

TABLE OF CONTENTS

| ​ | INDEPENDENT REGISTERED PUBLIC ACCOUNTINGFIRM | ​ |

INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FEES The Audit Committee works with our management in order to negotiate appropriate fees with EY and is ultimately responsible for approving those fees. The following is a summary and description of fees for services provided by EY in 2024